Oct4A is expressed by a subpopulation of prostate neuroendocrine cells

Paula Sotomayor, Alejandro Godoy, Gary J. Smith, Wendy J. Huss

Resultado de la investigación: Article

76 Citas (Scopus)

Resumen

BACKGROUND. Cancer stem cells are defined by their self-renewal and multi-potential capabilities and are hypothesized to be the source of primary and recurrent cancers. The stem cell properties of self-renewal and pluripotency in embryonic stem cells and germ cells are regulated by Oct4A, a splice variant of the POU5F1 (Oct3/4) gene, while the function of the alternative splice variant, Oct4B, is unknown. Rare cells that express Oct4 were identified in several somatic cancers, however, the differential contributions of the Oct4A and Oct4B variants were not determined. METHODS. Oct4A expression and co-localization with lineage markers was performed with PCR and immunohistochemistry. RESULTS. Rare Oct4A expressing cells are present in human benign and malignant prostate glands and the number of Oct4A expressing cells increases in prostate cancers with high Gleason scores. Oct4A expressing cells were non-proliferative, and did not co-express markers of basal epithelial cell or luminal epithelial cell differentiation, or AMACR, a marker of prostate cancer epithelial cells. A subpopulation of the Oct4A expressing cells co-expressed Sox2, an embryonic stem cell marker, but did not express other putative stem cell markers, such as ABCG2, NANOG or CD133. The majority of Oct4A expressing cells co-expressed chromogranin A, and a subset of Oct4A expressing cells co-expressed synaptophysin, both markers of neuroendocrine differentiation. CONCLUSION. The increased number of cells that expressed Oct4A in prostate cancer compared to benign prostate, and in cancers of increasing grade, suggests that Oct4A/Chromogranin A co-expressing cells represent neuroendocrine cells in prostate cancer. Prostate 69:401-410, 2009.

Idioma originalEnglish
Páginas (desde-hasta)401-410
Número de páginas10
PublicaciónProstate
Volumen69
N.º4
DOI
EstadoPublished - 1 mar 2009

Huella dactilar

Neuroendocrine Cells
Prostate
Prostatic Neoplasms
Chromogranin A
Epithelial Cells
Embryonic Stem Cells
Synaptophysin
Neoplastic Stem Cells
Neoplasm Grading
Differentiation Antigens
Germ Cells
Cell Differentiation
Neoplasms
Stem Cells
Cell Count
Immunohistochemistry
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Urology
  • Oncology
  • Medicine(all)

Citar esto

Sotomayor, P., Godoy, A., Smith, G. J., & Huss, W. J. (2009). Oct4A is expressed by a subpopulation of prostate neuroendocrine cells. Prostate, 69(4), 401-410. https://doi.org/10.1002/pros.20895
Sotomayor, Paula ; Godoy, Alejandro ; Smith, Gary J. ; Huss, Wendy J. / Oct4A is expressed by a subpopulation of prostate neuroendocrine cells. En: Prostate. 2009 ; Vol. 69, N.º 4. pp. 401-410.
@article{072dc30f8f794f648f40e26643e610be,
title = "Oct4A is expressed by a subpopulation of prostate neuroendocrine cells",
abstract = "BACKGROUND. Cancer stem cells are defined by their self-renewal and multi-potential capabilities and are hypothesized to be the source of primary and recurrent cancers. The stem cell properties of self-renewal and pluripotency in embryonic stem cells and germ cells are regulated by Oct4A, a splice variant of the POU5F1 (Oct3/4) gene, while the function of the alternative splice variant, Oct4B, is unknown. Rare cells that express Oct4 were identified in several somatic cancers, however, the differential contributions of the Oct4A and Oct4B variants were not determined. METHODS. Oct4A expression and co-localization with lineage markers was performed with PCR and immunohistochemistry. RESULTS. Rare Oct4A expressing cells are present in human benign and malignant prostate glands and the number of Oct4A expressing cells increases in prostate cancers with high Gleason scores. Oct4A expressing cells were non-proliferative, and did not co-express markers of basal epithelial cell or luminal epithelial cell differentiation, or AMACR, a marker of prostate cancer epithelial cells. A subpopulation of the Oct4A expressing cells co-expressed Sox2, an embryonic stem cell marker, but did not express other putative stem cell markers, such as ABCG2, NANOG or CD133. The majority of Oct4A expressing cells co-expressed chromogranin A, and a subset of Oct4A expressing cells co-expressed synaptophysin, both markers of neuroendocrine differentiation. CONCLUSION. The increased number of cells that expressed Oct4A in prostate cancer compared to benign prostate, and in cancers of increasing grade, suggests that Oct4A/Chromogranin A co-expressing cells represent neuroendocrine cells in prostate cancer. Prostate 69:401-410, 2009.",
keywords = "Neuroendocrine cell, Oct4, Prostate cancer",
author = "Paula Sotomayor and Alejandro Godoy and Smith, {Gary J.} and Huss, {Wendy J.}",
year = "2009",
month = "3",
day = "1",
doi = "10.1002/pros.20895",
language = "English",
volume = "69",
pages = "401--410",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "4",

}

Sotomayor, P, Godoy, A, Smith, GJ & Huss, WJ 2009, 'Oct4A is expressed by a subpopulation of prostate neuroendocrine cells', Prostate, vol. 69, n.º 4, pp. 401-410. https://doi.org/10.1002/pros.20895

Oct4A is expressed by a subpopulation of prostate neuroendocrine cells. / Sotomayor, Paula; Godoy, Alejandro; Smith, Gary J.; Huss, Wendy J.

En: Prostate, Vol. 69, N.º 4, 01.03.2009, p. 401-410.

Resultado de la investigación: Article

TY - JOUR

T1 - Oct4A is expressed by a subpopulation of prostate neuroendocrine cells

AU - Sotomayor, Paula

AU - Godoy, Alejandro

AU - Smith, Gary J.

AU - Huss, Wendy J.

PY - 2009/3/1

Y1 - 2009/3/1

N2 - BACKGROUND. Cancer stem cells are defined by their self-renewal and multi-potential capabilities and are hypothesized to be the source of primary and recurrent cancers. The stem cell properties of self-renewal and pluripotency in embryonic stem cells and germ cells are regulated by Oct4A, a splice variant of the POU5F1 (Oct3/4) gene, while the function of the alternative splice variant, Oct4B, is unknown. Rare cells that express Oct4 were identified in several somatic cancers, however, the differential contributions of the Oct4A and Oct4B variants were not determined. METHODS. Oct4A expression and co-localization with lineage markers was performed with PCR and immunohistochemistry. RESULTS. Rare Oct4A expressing cells are present in human benign and malignant prostate glands and the number of Oct4A expressing cells increases in prostate cancers with high Gleason scores. Oct4A expressing cells were non-proliferative, and did not co-express markers of basal epithelial cell or luminal epithelial cell differentiation, or AMACR, a marker of prostate cancer epithelial cells. A subpopulation of the Oct4A expressing cells co-expressed Sox2, an embryonic stem cell marker, but did not express other putative stem cell markers, such as ABCG2, NANOG or CD133. The majority of Oct4A expressing cells co-expressed chromogranin A, and a subset of Oct4A expressing cells co-expressed synaptophysin, both markers of neuroendocrine differentiation. CONCLUSION. The increased number of cells that expressed Oct4A in prostate cancer compared to benign prostate, and in cancers of increasing grade, suggests that Oct4A/Chromogranin A co-expressing cells represent neuroendocrine cells in prostate cancer. Prostate 69:401-410, 2009.

AB - BACKGROUND. Cancer stem cells are defined by their self-renewal and multi-potential capabilities and are hypothesized to be the source of primary and recurrent cancers. The stem cell properties of self-renewal and pluripotency in embryonic stem cells and germ cells are regulated by Oct4A, a splice variant of the POU5F1 (Oct3/4) gene, while the function of the alternative splice variant, Oct4B, is unknown. Rare cells that express Oct4 were identified in several somatic cancers, however, the differential contributions of the Oct4A and Oct4B variants were not determined. METHODS. Oct4A expression and co-localization with lineage markers was performed with PCR and immunohistochemistry. RESULTS. Rare Oct4A expressing cells are present in human benign and malignant prostate glands and the number of Oct4A expressing cells increases in prostate cancers with high Gleason scores. Oct4A expressing cells were non-proliferative, and did not co-express markers of basal epithelial cell or luminal epithelial cell differentiation, or AMACR, a marker of prostate cancer epithelial cells. A subpopulation of the Oct4A expressing cells co-expressed Sox2, an embryonic stem cell marker, but did not express other putative stem cell markers, such as ABCG2, NANOG or CD133. The majority of Oct4A expressing cells co-expressed chromogranin A, and a subset of Oct4A expressing cells co-expressed synaptophysin, both markers of neuroendocrine differentiation. CONCLUSION. The increased number of cells that expressed Oct4A in prostate cancer compared to benign prostate, and in cancers of increasing grade, suggests that Oct4A/Chromogranin A co-expressing cells represent neuroendocrine cells in prostate cancer. Prostate 69:401-410, 2009.

KW - Neuroendocrine cell

KW - Oct4

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=59849125058&partnerID=8YFLogxK

U2 - 10.1002/pros.20895

DO - 10.1002/pros.20895

M3 - Article

C2 - 19058139

AN - SCOPUS:59849125058

VL - 69

SP - 401

EP - 410

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 4

ER -